From post-COVID-19-associated myocarditis to hemopericardium: a dangerous domino effect

Francesco Bellanti; Ripalta Amato; Antonio Centola; Valeria Ercolano; Lucia Barbera; Annamaria Tesse; Grazia Divittorio; Cristiano Capurso; Aurelio Lo Buglio; Gianluigi Vendemiale

doi:10.26599/1671-5411.2023.05.008

Volume 20 Issue 5

May 2023

Turn off MathJax

Article Contents

Article Navigation > Journal of Geriatric Cardiology > 2023 > 20(5): 391-396

Please cite this article as: Bellanti F, Amato R, Centola A, Ercolano V, Barbera L, Tesse A, Divittorio G, Capurso C, Lo Buglio A, Vendemiale G. From post-COVID-19-associated myocarditis to hemopericardium: a dangerous domino effect. J Geriatr Cardiol 2023; 20(5): 391−396. DOI: 10.26599/1671-5411.2023.05.008

Citation:

Please cite this article as: Bellanti F, Amato R, Centola A, Ercolano V, Barbera L, Tesse A, Divittorio G, Capurso C, Lo Buglio A, Vendemiale G. From post-COVID-19-associated myocarditis to hemopericardium: a dangerous domino effect. J Geriatr Cardiol 2023; 20(5): 391−396. DOI: 10.26599/1671-5411.2023.05.008

Citation:

PDF( 722 KB)

From post-COVID-19-associated myocarditis to hemopericardium: a dangerous domino effect

doi: 10.26599/1671-5411.2023.05.008

1.
Department of Medical and Surgical Sciences, University of Foggia, viale Pinto 1, 71122 Foggia, Italy
2.
Department of Internal and Geriatric Medicine, Policlinico Riuniti, viale Pinto 1, 71122 Foggia, Italy
3.
Department of Cardiology, Policlinico Riuniti, viale Pinto 1, 71122 Foggia, Italy

More Information

Corresponding author: francesco.bellanti@unifg.it
Publish Date: 2023-05-28

Abstract

FullText(HTML)

References(28)

References

[1]	Sah P, Fitzpatrick MC, Zimmer CF, et al. Asymptomatic SARS-CoV-2 infection: A systematic review and meta-analysis. Proc Natl Acad Sci U S A 2021; 118: e2109229118. doi: 10.1073/pnas.2109229118
[2]	Long B, Carius BM, Chavez S, et al. Clinical update on COVID-19 for the emergency clinician: Presentation and evaluation. Am J Emerg Med 2022; 54: 46−57. doi: 10.1016/j.ajem.2022.01.028
[3]	Schulze H, Charles JJ, Trampe N, et al. Cross-sectional analysis of clinical aspects in patients with long-COVID and post-COVID syndrome. Front Neurol 2022; 13: 979152. doi: 10.3389/fneur.2022.979152
[4]	Soriano JB, Murthy S, Marshall JC, et al. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis 2022; 22: e102−e107. doi: 10.1016/S1473-3099(21)00703-9
[5]	Mohammad KO, Lin A, Rodriguez JBC. Cardiac manifestations of post-acute COVID-19 infection. Curr Cardiol Rep 2022; 24: 1775−1783. doi: 10.1007/s11886-022-01793-3
[6]	Gaine S, Devitt P, Coughlan JJ, et al. COVID-19-associated myocarditis presenting as new-onset heart failure and atrial fibrillation. BMJ Case Rep 2021; 14: e244027. doi: 10.1136/bcr-2021-244027
[7]	Zuin M, Rigatelli G, Bilato C, et al. One-Year Risk of Myocarditis After COVID-19 Infection: A Systematic Review and Meta-analysis. Can J Cardiol 2022. DOI: 10.1016/j.cjca.2022.12.003. Published online first: Dec 12, 2022.
[8]	Hernandez I, Gabriel N, He M, et al. COVID-19 and anticoagulation for atrial fibrillation: an analysis of US nationwide pharmacy claims data. J Am Heart Assoc 2021; 10: e023235. doi: 10.1161/JAHA.121.023235
[9]	Schiavone M, Sozzi FB, Gasperetti A, et al. Clinical management of new-onset atrial fibrillation in COVID-19 patients referred to a tertiary cardiac arrhythmia center after hospital discharge. J Clin Med 2022; 11: 5661. doi: 10.3390/jcm11195661
[10]	Carnicelli AP, Hong H, Connolly SJ, et al. Direct oral anticoagulants versus warfarin in patients with atrial fibrillation: patient-level network meta-analyses of randomized clinical trials with interaction testing by age and sex. Circulation 2022; 145: 242−255. doi: 10.1161/CIRCULATIONAHA.121.056355
[11]	Xu B, MacIsaac A. Life-threatening haemorrhagic pericarditis associated with rivaroxaban. Int J Cardiol 2014; 174: e75−e76. doi: 10.1016/j.ijcard.2014.04.151
[12]	Rizzi DA, Pedersen SA. Causality in medicine: towards a theory and terminology. Theor Med 1992; 13: 233−254. doi: 10.1007/BF00489201
[13]	Huseynov A, Akin I, Duerschmied D, et al. Cardiac Arrhythmias in post-COVID syndrome: prevalence, pathology, diagnosis, and treatment. Viruses 2023; 15: 389. doi: 10.3390/v15020389
[14]	Liguori C, Farina D, Vaccher F, et al. Myocarditis: imaging up to date. Radiol Med 2020; 125: 1124−1134. doi: 10.1007/s11547-020-01279-8
[15]	Chung MK, Zidar DA, Bristow MR, et al. COVID-19 and cardiovascular disease: from bench to bedside. Circ Res 2021; 128: 1214−1236. doi: 10.1161/CIRCRESAHA.121.317997
[16]	Lazzerini PE, Laghi-Pasini F, Boutjdir M, et al. Inflammatory cytokines and cardiac arrhythmias: the lesson from COVID-19. Nat Rev Immunol 2022; 22: 270−272. doi: 10.1038/s41577-022-00714-3
[17]	Fujinami RS, von Herrath MG, Christen U, et al. Molecular mimicry, bystander activation, or viral persistence: infections and autoimmune disease. Clin Microbiol Rev 2006; 19: 80−94. doi: 10.1128/CMR.19.1.80-94.2006
[18]	Marraki ZE, Bouzhir A, Nguadi J, et al. Post-COVID myocarditis simulating acute coronary syndrome: Case report. Radiol Case Rep 2023; 18: 665−670. doi: 10.1016/j.radcr.2022.11.023
[19]	Baksi AJ, Kanaganayagam GS, Prasad SK. Arrhythmias in viral myocarditis and pericarditis. Card Electrophysiol Clin 2015; 7: 269−281. doi: 10.1016/j.ccep.2015.03.009
[20]	Imazio M, Trinchero R. Myopericarditis: etiology, management, and prognosis. Int J Cardiol 2008; 127: 17−26. doi: 10.1016/j.ijcard.2007.10.053
[21]	Raatikainen P, Lassila R. COVID-19: another reason for anticoagulation in patients with atrial fibrillation. Heart 2022; 108: 902−904. doi: 10.1136/heartjnl-2022-320845
[22]	January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014; 64: e1−e76. doi: 10.1016/j.jacc.2014.03.022
[23]	Julia S, James U. Direct Oral Anticoagulants: A Quick Guide. Eur Cardiol 2017; 12: 40−45. doi: 10.15420/ecr.2017:11:2
[24]	Sheikh AB, Shah I, Sagheer S, et al. Hemopericardium in the Setting of Direct Oral Anticoagulant Use: An Updated Systematic Review. Cardiovasc Revasc Med 2022; 39: 73−83. doi: 10.1016/j.carrev.2021.09.010
[25]	Asad ZUA, Ijaz SH, Chaudhary AMD, et al. Hemorrhagic cardiac tamponade associated with apixaban: a case report and systematic review of literature. Cardiovasc Revasc Med 2019; 20: 15−20. doi: 10.1016/j.carrev.2019.04.002
[26]	Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239−245. doi: 10.1038/clpt.1981.154
[27]	Fernandez S, Lenoir C, Samer C, et al. Drug interactions with apixaban: A systematic review of the literature and an analysis of VigiBase, the World Health Organization database of spontaneous safety reports. Pharmacol Res Perspect 2020; 8: e00647.
[28]	Shah N, Saleh M, Jyala A, et al. COVID-19-Induced Myopericarditis Leading to Cardiac Tamponade: An Unusual Case Presentation. Cureus 2022; 14: e27158.